Rising Type 2 diabetes in US children: Mounjaro-like drugs help manage weight and blood sugar; Lancet study reveals
Mounjaro shows promise for young patients with Type 2 diabetes and obesity. A recent study reveals its active ingredient, tirzepatide, lowers blood sugar and promotes weight loss in children aged 10 and above. The trial demonstrates significant A1C reductions and BMI improvements. Eli Lilly seeks regulatory approval to expand Mounjaro's availability.
Mounjaro shows promise for young patients with Type 2 diabetes and obesity. A recent study reveals its active ingredient, tirzepatide, lowers blood sugar and promotes weight loss in children aged 10 and above. The trial demonstrates significant A1C reductions and BMI improvements. Eli Lilly seeks regulatory approval to expand Mounjaro's availability.
